Status:
COMPLETED
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Lead Sponsor:
Pain and Analgesia Imaging and Neuroscience Group
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Facial Neuropathy
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional magnetic resonance imaging (fMR...
Detailed Description
Currently there are no pharmacological agents that can control neuropathic pain akin to the efficacy of antibiotics for bacterial infection. All current neuropathic pain drugs have approximately the s...
Eligibility Criteria
Inclusion
- 18-60 years of age
- Right-handed non-smokers
- Diagnosed with facial pain
- Continuous pain for more than 3 months
- Spontaneous pain greater than 3 of 10
- Allodynia to brush greater than 5 of 10
Exclusion
- Medications
- Depression
- Significant medical problems
- Claustrophobia
- Abnormal EKG
- Significant drug or alcohol history
- Positive drug screen
- Weight greater than 285 lbs
- History of allergy to anticonvulsants
- Tattoos with metallic ink on upper body
- Any neurostimulator devices, or metal cochlear, ocular, or cardiac implants or other metal near vital areas
- Exposure to shrapnel or metal filings
- Other metallic surgical hardware
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00243152
Start Date
October 1 2005
End Date
July 1 2008
Last Update
December 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital Neuroimaging Center, 115 Mill Street
Belmont, Massachusetts, United States, 02478